Drug Discovery Companies

Tempus AI

Chicago, United States

Tempus provides a platform combining comprehensive clinical and molecular data with artificial intelligence, primarily serving the oncology space. Their core offering is an operating system built upon the world’s largest library of such data, enhanced by recent advancements in generative AI like their clinical co-pilot, David, and digital pathology capabilities acquired through Paige. Tempus targets physicians, pharmaceutical companies, and patients seeking data-driven insights to improve cancer treatment decisions and accelerate drug development.

Xaira Therapeutics

San Francisco, United States

Xaira Therapeutics is building a generative AI platform focused on de novo protein design and drug candidate creation, leveraging advancements from the technology behind AlphaFold. The company’s core innovation lies in applying AI to not just predict protein structures, but to generate novel protein therapeutics with optimized properties for a range of diseases. Backed by a $1 billion Series A funding round, Xaira Therapeutics aims to accelerate drug discovery beyond traditional methods and is initially focusing on developing therapeutics for currently undruggable targets.

Insitro

South San Francisco, United States

Insitro leverages high-throughput phenotypic screening and machine learning to build predictive models of human biology, focusing initially on diseases like NASH and heart failure. Their platform combines large-scale experimental data – including cellular assays and human genetic data – with proprietary machine learning algorithms to identify and validate drug targets and predict clinical trial success. Notably, Insitro has established collaborations with pharmaceutical companies like Bristol Myers Squibb and Roche to apply their technology to specific disease areas and advance novel therapeutics.

Insilico Medicine

Hong Kong, Hong Kong

Insilico Medicine is a Hong Kong-based biotechnology company applying generative AI to accelerate the discovery and development of novel therapeutics. Their core technology is Pharma.AI, an end-to-end platform utilizing deep learning for target identification, molecule generation, and clinical trial prediction. Insilico Medicine focuses on discovering drugs for age-related diseases and extending healthy longevity, aiming to reduce the time and cost associated with traditional pharmaceutical R&D.

Valo Health

Boston, United States

Valo Health is a U.S.-based company applying artificial intelligence to accelerate pharmaceutical drug discovery and development. Their core product is the Opal Computational Platform™, which integrates machine learning with extensive human tissue and patient data to identify and advance potential drug candidates. Valo targets the pharmaceutical industry by offering a technology platform designed to reduce the time and cost associated with bringing novel therapies to market.

Lila Sciences

San Francisco, United States

Lila Sciences builds AI-driven 'science factories' that pair machine learning with autonomous laboratories to accelerate scientific discovery across life sciences, chemistry, and materials.

PathAI

Boston, United States

PathAI builds AI-powered image analysis tools specifically for pathology, offering products like their FDA Breakthrough Device designated algorithm for detecting minimal residual disease in breast cancer and their coreDSP platform for digital pathology workflow optimization. Their key innovation lies in applying deep learning to whole slide images, enabling more accurate and reproducible diagnosis, biomarker identification, and patient stratification in clinical trials. PathAI partners with leading pharmaceutical companies like Bristol Myers Squibb and Roche, and has secured over $200 million in funding to accelerate drug development and improve cancer diagnosis.

Owkin

Paris, France

Owkin is a French AI company focused on accelerating drug discovery and precision medicine through advanced analysis of complex biological data. Their core product, the K PRO platform, utilizes agentic AI – a system of autonomous AI agents – to uncover causal relationships within multimodal patient data sourced from leading research institutions. Owkin serves pharmaceutical companies and academic researchers seeking to improve R&D efficiency and identify novel therapeutic targets by leveraging AI-driven insights beyond traditional analytical methods.

Terray Therapeutics

Pasadena, United States

Terray Therapeutics combines high-throughput chemistry with machine learning to design small-molecule drugs, generating large proprietary datasets to train its models for drug discovery.

BPGbio

Framingham, United States

BPGbio is a biotechnology company that applies AI and causal machine learning to biological data to discover drugs and biomarkers across oncology, neurology, and rare diseases.

BioAge Labs

Richmond, United States

BioAge Labs is a US-based biotechnology company focused on developing therapeutics for cardiometabolic diseases by targeting the biological processes of aging. Their core technology is a human-first discovery platform that leverages decades of proprietary multi-omics data to identify and validate novel aging-related drug targets. Currently, BioAge is advancing BGE-102, a program targeting chronic inflammation, and a preclinical apelin receptor agonist with potential for significant weight loss, both aimed at addressing age-related metabolic dysfunction.

Atomwise

San Francisco, United States

Atomwise develops a deep learning platform, leveraging convolutional neural networks to predict the binding affinity of small molecules to proteins – accelerating the identification of potential drug candidates. Their AI superplatform virtually screens trillions of compounds, identifying novel molecules with potential in areas like immune and inflammatory diseases, and has resulted in multiple programs advancing towards clinical development. Notably, Atomwise has partnered with organizations like the National Institutes of Health and has demonstrated success in repurposing existing drugs for new applications, including identifying potential treatments for Ebola and COVID-19.

Verge Genomics

San Francisco, United States

Verge Genomics has developed CONVERGE®, an AI-powered drug discovery platform utilizing a large, proprietary human multi-omics database to identify and validate drug candidates for neurodegenerative diseases. Their platform leverages machine learning to analyze human tissue data, enabling the rapid identification of novel targets and accelerating drug development – most notably, their lead compound VRG50635, a PIKfyve inhibitor for ALS, entered clinical trials just four years after initial research. Currently focused on ALS, Parkinson’s Disease, and Frontotemporal Dementia, Verge aims to deliver breakthrough treatments for diseases with limited or no effective therapies.

EvolutionaryScale

New York, United States

EvolutionaryScale develops generative AI models for de novo protein design and understanding, most notably the ESM-3 family of protein language models. Their core innovation lies in leveraging large-scale protein sequence data to enable the creation of novel proteins with desired functions – demonstrated by the successful in silico design and synthesis of esmGFP, a fluorescent protein evolved beyond natural limitations. Targeting pharmaceutical companies, biotechnology firms, and academic research labs, EvolutionaryScale provides access to ESM-3 via API and open-source models (ESM-3-open) to accelerate drug discovery and protein engineering efforts, backed by $142M in seed funding.

Aqemia

Paris, France

Aqemia is a Paris-based drug-discovery company that combines generative AI with quantum-inspired physics algorithms to design new drug candidates faster than conventional methods. A spin-out of Ecole Normale Superieure, it has partnerships with Sanofi, Servier, and Johnson & Johnson.

Healx

Cambridge, United Kingdom

Healx is a UK-based company applying artificial intelligence to accelerate drug discovery for rare diseases. Their core technology utilizes AI-driven drug repurposing – identifying and developing existing compounds for new applications – to build a pipeline of potential therapies. Healx focuses on addressing the 90% of rare diseases lacking treatment by de-risking the drug development process and efficiently scaling programs for conditions with limited patient populations.

Cradle

Amsterdam, Netherlands

Cradle develops a generative AI platform for de novo protein design, enabling researchers to create and optimize proteins with desired properties. Their technology utilizes machine learning models trained on proprietary and user-supplied experimental data to generate novel protein sequences and predict their characteristics, accelerating the drug discovery and protein engineering processes. Cradle targets biotechnology and pharmaceutical companies, and their platform aims to reduce the time and cost associated with traditional protein development pipelines by minimizing the need for iterative lab experiments.

Genesis Therapeutics

Burlingame, United States

Genesis Therapeutics is a U.S.-based biotech company focused on de novo drug design for previously intractable protein targets. Their core technology is GEMS, a proprietary molecular AI platform integrating AI and physics-based modeling to generate highly potent and selective drug candidates. Genesis Therapeutics targets pharmaceutical companies and research institutions seeking to accelerate discovery for complex targets that have historically proven difficult to address with traditional methods.

54gene

Lagos, Nigeria

54gene builds a pan-African genomic database to improve drug discovery and development for diseases disproportionately impacting African populations. Utilizing AI-powered analysis of this data, they identify genetic factors relevant to disease and accelerate the creation of targeted therapeutics. Their unique value proposition lies in addressing the significant underrepresentation of African genomes in existing biomedical research, enabling more effective and equitable healthcare solutions.

Proscia

Philadelphia, United States

Proscia develops Concentriq, a digital pathology platform leveraging computer vision and AI to accelerate cancer diagnostics and drug discovery. Their core technology focuses on analyzing pathology images to improve biomarker identification and streamline clinical trials. Notably, Proscia’s platform was ranked #1 in the 2026 Best in KLAS awards, demonstrating strong customer satisfaction within the life sciences and healthcare sectors.

Atomic AI

San Francisco, United States

Atomic AI is a U.S.-based biotechnology company focused on discovering novel RNA-targeted therapeutics. Their core technology is a deep learning platform that integrates computational modeling with proprietary wet-lab assays to identify and develop small molecule drugs and RNA-based medicines. Atomic AI targets pharmaceutical companies and research institutions seeking to expand their pipelines with innovative RNA-focused therapies.

Bioptimus

Paris, France

Bioptimus is building universal AI foundation models for biology. Their models understand biological systems to accelerate drug discovery and healthcare innovation.

Profluent

Berkeley, United States

Profluent uses large language models to design novel proteins for therapeutic applications. Developed OpenCRISPR, the first AI-designed gene editor used to edit human genomes.

Intelligencia AI

New York, Greece

Intelligencia AI uses curated biomedical data and machine learning to predict the probability of technical and regulatory success for drugs in clinical trials, helping pharma de-risk development. Founded in 2017 (New York HQ, Athens office) by Dimitrios Skaltsas and Vangelis Vergetis; ~110 staff.

Ingenix

Warsaw, Poland

Ingenix is a Warsaw-based deep-tech startup building a multimodal generative-AI co-pilot that simulates clinical trials using digital twins. Its foundation model is trained on genomic, transcriptomic and imaging data to predict clinical endpoints and adverse events before physical trials begin, aiming to reduce drug-development failure rates. It raised a EUR 9 million seed round led by Inovo.vc with OTB Ventures and IFC.

BenevolentAI

London, United Kingdom

BenevolentAI is a UK-based company that leverages a proprietary knowledge graph and machine learning to accelerate drug discovery and development. Their platform analyzes complex biomedical data and scientific literature to identify promising drug candidates and targets, supporting R&D decisions for pharmaceutical and biotechnology companies. BenevolentAI differentiates itself through a decade of investment in building a uniquely comprehensive and interconnected life science intelligence system.

Exscientia

Oxford, United Kingdom

Recursion is a clinical-stage technology company applying artificial intelligence to drug discovery and development. Their Recursion OS platform integrates extensive biological and chemical datasets – exceeding 65 petabytes – with automated experimentation and machine learning to rapidly identify drug candidates and optimize molecule design. Targeting conditions with high unmet need like cancer and rare diseases, Recursion aims to significantly improve the efficiency and reduce the failure rate traditionally associated with pharmaceutical research.

Isomorphic Labs

London, United Kingdom

Isomorphic Labs is a UK-based AI company applying advanced machine learning to accelerate drug discovery and molecular design. Building upon the AlphaFold protein structure prediction technology, they develop predictive and generative AI models to design novel molecules and anticipate drug performance. Their focus is on leveraging AI to address complex diseases and fundamentally transform the pharmaceutical research process for potential breakthroughs in medicine.

InstaDeep

Tunis, Tunisia

InstaDeep develops AI-powered decision-making systems, specializing in deep reinforcement learning and combinatorial optimization algorithms like those used in their DeepMind-collaborated protein folding work with AlphaFold. Their technology is applied to complex challenges in life sciences – notably demonstrated by their collaboration with BioNTech to accelerate drug discovery and vaccine development – and industrial applications like logistics and supply chain optimization. Acquired by BioNTech in 2023, InstaDeep leverages GPU-accelerated computing and has achieved research breakthroughs presented at leading AI conferences like NeurIPS, solidifying their position as a leader in applied AI research.

Anivance AI

Boston, Taiwan

Anivance AI (久浪智醫) combines organ-on-chip systems, lab automation and multi-agent AI to model human biology (lung, liver, heart, kidney, tumor) and accelerate drug development without animal testing. Founded in Taiwan by Dr. Guan-Yu Chen; raised NT$72M in seed funding.

Veeva Systems

Pleasanton, United States

Veeva Systems provides cloud-based software solutions specifically for the life sciences industry, encompassing research & development, quality management, and commercial operations. Their core offering is a unified clinical platform leveraging AI and data analytics to accelerate study timelines, streamline regulatory compliance, and improve data quality. Veeva targets pharmaceutical and biotechnology companies of all sizes, offering a consolidated system to manage critical processes from drug development through commercialization.

Recursion

Salt Lake City, United States

Recursion Pharmaceuticals leverages extensive biological and chemical datasets – exceeding 65 petabytes encompassing phenomics, transcriptomics, and patient data – to power its Recursion OS drug discovery platform. This platform utilizes computer vision, machine learning, and a proprietary supercomputer, BioHive-2, to analyze cellular images and predict drug efficacy, significantly accelerating hit identification and IND-enabling studies. Currently, Recursion is advancing a pipeline of potential therapies, including REC-3565 for B-cell lymphomas which is in Phase 1 clinical trials, and has established strategic partnerships with pharmaceutical and technology leaders to expand its AI-driven drug discovery capabilities.

Chai Discovery

San Francisco, United States

Chai Discovery develops generative AI models focused on de novo molecular design for drug discovery. Their core technology utilizes a proprietary transformer-based architecture to predict and engineer biomolecular interactions, enabling the creation of novel protein and small molecule therapeutics. Recently securing $130M in Series B funding, Chai Discovery targets the pharmaceutical industry with a platform aimed at accelerating the identification of promising drug candidates.

Iambic Therapeutics

San Diego, United States

Iambic Therapeutics develops AI-powered platforms for de novo drug design, focusing on challenging targets with unmet medical needs. Their core technology combines multimodal transformers and protein co-folding AI – specifically “Enchant” and “NeuralPLexer” – with a high-throughput experimental platform to rapidly iterate between molecular design and biological validation. Founded in 2019, Iambic aims to deliver diverse, high-quality drug leads by exploring novel mechanisms of action within vast chemical spaces.

Basecamp Research

London, United Kingdom

Basecamp Research develops generative AI models for de novo molecular design, specializing in creating novel small molecule drug candidates. Their core technology utilizes a proprietary reinforcement learning platform to optimize molecular properties and predict synthetic accessibility. The company primarily serves pharmaceutical and biotechnology companies, and recently achieved notable success in generating compounds with high potential for challenging drug targets like protein-protein interactions.

Latent Labs

London, United Kingdom

Latent Labs develops generative AI models focused on de novo molecular design for applications in drug discovery and synthetic biology. Their core product suite, including models like Latent-X, Latent-X2, and Latent-Y, utilizes frontier AI to generate novel proteins, antibodies, and optimize existing enzymes at the atomic level. Founded in 2024, the company targets pharmaceutical and biotechnology partners, demonstrated by the lab validation of Latent-Y as a drug design agent.

Arc Institute

Palo Alto, United States

Arc Institute is a US-based nonprofit research organization applying artificial intelligence to fundamental questions in biology and drug discovery. Their core technology is Evo 2, a large biological foundation model trained on extensive genomic data, used in conjunction with frameworks like MULTI-evolve for protein engineering and prediction. Research focuses on areas including microbiome-brain signaling, nutritional genomics, and genetic interaction mapping, with published work demonstrating advancements in understanding aging and disease mechanisms.

FutureHouse

San Francisco, United States

FutureHouse is a U.S.-based non-profit research organization developing AI agents to automate scientific research, initially focused on biology and materials science. Their core technology is OXtal, an all-atom diffusion model for predicting crystal structures from molecular graphs. Funded by philanthropic investment, FutureHouse aims to democratize access to advanced scientific expertise and accelerate discovery timelines, rather than pursuing commercial applications.

FinalDose

London, United Kingdom

FinalDose is developing a programmable DNA-targeting drug: a single smart molecule that, given a guide for a disease-causing genetic sequence, recognizes target DNA and triggers a cell kill-switch, aiming to address previously 'undruggable' cancer targets such as MYC, TP53, and APC. Founded 2025 in London by three Oxford PhDs (Jeff Liu, Li-Yao Huang, Steven Lin); Y Combinator-backed.

Proteinea

Cairo, Egypt

Proteinea is an Egyptian TechBio startup that applies AI and computational models to protein engineering and biotherapeutic discovery, focusing on antibody Fc-domain engineering to improve half-life and immune function. The founders describe their goal as building a domain-specific AI platform for drug discovery. It is backed by investors including Shorooq Partners and has been supported by IndieBio and KAUST.